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THE CASE FOR FIELD PREEMPTION OF STATE
LAWS IN DRUG CASES
Richard A. Epstein*

INTRODUCTION: PREEMPTION IN FLUX
Catherine Sharkey‘s essay, What Riegel Portends for FDA Preemption
of State Law Product Liability Claims, represents an ingenious effort to
work between the horns of the most pressing dilemma in today‘s law of
federal preemption with her ―agency reference model‖ of preemption.1 This
issue is hot today because the Supreme Court recently held in Riegel v.
Medtronic, Inc. that the Medical Devices Act preempted a plaintiff‘s state
product liability claims alleging defective design of a balloon catheter after
plaintiff suffered grievous injuries when the device ruptured inside his right
coronary artery.2 It is worthy of note that here the treating physician made
two controversial decisions: (1) he used the catheter on a patient whom
FDA warnings classified as unfit for the treatment; and (2) he overinflated
the catheter.3 The problem of FDA preemption also arises in the context of
a drug manufacturer‘s duty to warn in a case scheduled to come before the
Supreme Court next year, Wyeth v. Levine.4 In that case, the Vermont Supreme Court upheld a damage award on the ground that Wyeth should have
warned the plaintiff against using its drug, Phenergan, in a risky procedure
that the FDA had explicitly authorized. More specifically, the FDAapproved warning label allowed Phenergan to be injected intravenously by
a so-called ―IV push,‖ or rapid injection into a vein by syringe, so long as
physicians were alert of the risk of hitting an artery instead of a vein. The
plaintiff suffered gangrene and consequent loss of a limb when the IV
needle mistakenly punctured the artery. Plaintiff argued that Wyeth‘s label
*
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Catherine M. Sharkey, What Riegel Portends for FDA Preemption of State Law Products Liability
Claims, 102 NW. U. L. REV. COLLOQUY 415 (2008) [hereinafter Sharkey, What Riegel Portends], available at http://www.law.northwestern.edu/lawreview/colloquy/2008/24/LRColl2008n24Sharkey.pdf
(link).
2
Riegel v. Medtronic, Inc., 128 S. Ct. 999 (2008) (link).
3
Id. at 1005.
4
Levine v. Wyeth, 2006 VT 107, 944 A.2d 179 (sustaining jury verdict), cert. granted, 128 S. Ct.
1118 (U.S. Jan. 18, 2008) (No. 06-1249) (link).
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―should not have allowed IV push‖—period.5
To understand the legal issues raised by these two cases, it is useful to
set the background with a thumbnail sketch of the modern law of preemption. All parties agree that some principles of interpretation are needed to
work out the interrelationships between federal and state action that covers
the same sphere of action. It is understood as well that the law of preemption divides itself into two halves. The first half deals with express preemption, which holds that if the federal government makes it clear—itself a
term that turns out often to be unclear—that its statute preempts the state
law, then the issue is over. Under the Supremacy Clause6 of the United
States Constitution, the lowliest federal action trumps the most grandiose
state pronouncement. Conversely, if the federal statute makes it clear that
the state law may peacefully coexist with it, a system of dual enforcement is
appropriate.
In many cases, of course, the question of preemption is not resolved by
express preemption, at which point the common view holds that there are
three possible grounds for implied preemption. The strictest standard allows for preemption only in cases of actual conflict, such that there must be
a clear inconsistency between what the federal government and the state
government each allow or require. Second, it is often stated that the
preemption in question only arises in those cases where the imposition of
the state liability will frustrate the ends of the federal statute. Finally, a
third form of preemption argues that preemption does not require this form
of explicit conflict, but is satisfied if it appears that the federal statute has
occupied the field, blocking state efforts to impose sanctions within that
field even if there is no explicit conflict. For our purposes, the first and
third forms of preemption are the most relevant ones. Drug cases are more
problematic than device cases because the Medical Devices Act does contain an explicit preemption provisions for medical devices, in contrast to
drug cases, which are subject to no explicit form of preemption.7
Professor Sharkey‘s distinctive contribution to this debate is her careful
elaboration of the ―agency reference model‖ of preemption, which enriches
the debate over preemption by consciously incorporating administrative law
principles resting on the twin pillars of Chevron U.S.A., Inc. v. Natural Resources Defense Council, Inc.8 and Skidmore v. Swift & Co.9 Sharkey‘s
5

Id. at 182.
U.S. CONST. art. VI, cl. 2.
7
See Medical Device Amendments of 1976 § 521, 21 U.S.C. § 360k (2000) (link):
(a) Except as provided in subsection (b), no State or political subdivision of a State may establish
or continue in effect with respect to a device intended for human use any requirement—
6

(1) which is different from, or in addition to, any requirement applicable under this chapter to the
device, and
(2) which relates to the safety or effectiveness of the device or to any other matter included in a
requirement applicable to the device under this chapter.
8
467 U.S. 837 (1984) (link).
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―agency reference model‖ treats Chevron and Skidmore as defining an administrative universe in which the level of deference given an administrative action increases with thoroughness and formality of the processes that
generate the disputed ruling.10 Sharkey‘s proposal, elaborated with her customary vigor and clarity in her article on Riegel, explains how the key interpretive tools of the administrative state can shed light on the preemption
question.
This brief Comment renews my defense of strong field preemption for
FDA regulation. In Part I, I shall set out the emergence of modern preemption law in light of the vast expansion of federal power after the New Deal
with special reference to two cases of great current concern, Riegel11 and
Levine.12 Thereafter, in Part II, I shall comment first not on Professor Sharkey‘s article, but on a recent essay by David Kessler and David Vladeck
that takes the strong view that the doctrine of implied preemption should
not be applied in duty-to-warn drug cases.13 Then, in Part III, I address Professor Sharkey‘s agency model, and lastly, in Part IV, I offer a brief capitulation of my field preemption position.
I. PREEMPTION AFTER THE NEW DEAL
Historically, the consolidation of the New Deal administrative state
meant the federal government faced few, if any, limitations on the scope of
its power given the expansive reading of the Commerce Clause.14 This rapid expansion of federal power took place in an environment highly sympathetic to regulation at both the national and the state levels. State powers of
regulation have never been constrained by the federal constitutional doctrine of enumerated powers. But post-1937, the broad construction of the
Commerce Clause gave the federal government total power to regulate in
areas formerly reserved to the states, except in the most marginal of cases.15
9

323 U.S. 134 (1944) (link).
For a discussion of the various ins and outs of judicial deference to administrative decisions, see
Kristin E. Hickman & Matthew D. Kreuger, In Search of the Modern Skidmore Standard, 107 COLUM.
L. REV. 1235 (2007) (link); Thomas W. Merrill, The Mead Doctrine: Rules and Standards, Meta-Rules
and Meta-Standards, 54 ADMIN. L. REV. 807 (2002) (link).
11
Riegel v. Medtronic, Inc., 128 S. Ct. 999 (2008).
12
Levine v. Wyeth, 2006 VT 107, 944 A.2d 179 (sustaining jury verdict), cert. granted, 128 S. Ct.
1118 (U.S. Jan. 18, 2008) (No. 06-1249).
13
David A. Kessler & David C. Vladeck, A Critical Examination of the FDA’s Efforts to Preempt
Failure-to-Warn Claims, 96 GEO. L.J. 461 (2008) (link).
14
U.S. CONST. art. I, § 8, cl. 3. For the classic defense of the expansive view of the commerce
clause, see Robert Stern, The Commerce Clause and the National Economy, 59 HARV. L. REV. 645
(1946).
15
See Richard A. Epstein, The Federalism Decisions of Justices Rehnquist and O’Connor: Is Half a
Loaf Enough?, 58 STAN. L. REV. 1793, 1801–04 (2006). The decision in United States v. Lopez, 514
U.S. 549 (1995) (link), struck down a statute that prohibited the possession of firearms within 1,000 feet
of a school. But in so doing it solidified the holding in Wickard v. Filburn, 317 U.S. 111 (1942), which
is the current fount of federal power. See Gonzales v. Raich, 545 U.S. 1, 16–17 (2005) (―Our case law
10
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Riegel and Levine offer an effective window around which to organize
a discussion of preemption in the modern regulatory debate. What should
be done to ease the tension that arises when state and federal governments
regulate concurrently, arguably in inconsistent ways? We should not work
ourselves into a deep philosophical funk that regards the federal government as congenitally unable to speak with a clear voice. Of course it can be
done.16 However, as Sharkey rightly points out, passing federal regulation
is not merely a grammatical exercise. It is also a highly political one, where
sides jockey for position on the key question of whether state actions will
be allowed in an area once the federal government has entered the field.
This tension is real enough when both the federal and state government act
through regulation. The federal statutes clearly preempt state ―requirements‖ resulting from direct legislative or administrative action. The question of whether common law actions that can compel action are preempted
is much closer, and there has been some division of opinion.17 But the
stakes are a thousand-fold higher when the question turns to whether the
federal statute will trump state law tort causes of action that have expanded
vastly since the adoption of the Second Restatement of Torts, which was
published in 1966. All too often Congress combines a provision that first
preempts state law but then expressly preserves common law rights of action.18 What‘s a judge to do when Congress tries to square the circle?
Generally speaking, three schools of thought have arisen to deal with
this question. The first of these rests on what is commonly termed the ―presumption against preemption,‖ which means that all doubtful statutes
should be construed in ways that do not block the imposition of additional
sanctions at the state level. Justice Douglas‘s famous passage in Rice v.
Santa Fe Elevator Corp. put it as follows:
Congress legislated here [on the matter of warehouse receipts] in a field which
the States have traditionally occupied. So we start with the assumption that the
firmly establishes Congress‘ power to regulate purely local activities that are part of an economic ‗class
of activities‘ that have substantial effect on interstate commerce. . . . As we stated in Wickard, ‗even if
appellee‘s activity be local and though it may not be regarded as commerce, it may still . . . be reached
by Congress if it exerts a substantial economic effect on interstate commerce.‘‖) (quoting Wickard, 317
U.S. at 125) (link).
16
Easy cases are in practice hard to find, in part because the only cases that make it to the Supreme
Court have some genuine difficulty. One candidate for the easy class is United States v. Locke, 529 U.S.
89 (2000), preempting various state efforts to impose comprehensive regulation of interstate vessels
while in state waters.
17
Compare Cipollone v. Liggett Group, Inc., 505 U.S. 504 (1992) (link), with Bates v. Dow Agrosciences L.L.C., 544 U.S. 431 (2005) (link).
18
See Sharkey, What Riegel Portends, supra note 1, at 416 n.5 (citing National Traffic and Motor
Vehicle Safety Act of 1966, 15 U.S.C. § 1392(d) (1988) (current version at 49 U.S.C. § 30103(b) (2000)
(preemption clause); id. § 1397(k) (current version at 49 U.S.C. § 30103(e) (2000) (savings clause);
Consumer Product Safety Act, 15 U.S.C. § 2075(a) (2000) (preemption clause); id. § 2074(a) (savings
clause); Federal Boat Safety Act of 1971, 46 U.S.C. § 4306 (2000) (preemption clause); id. § 4311(g)
(savings clause)).
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historic police powers of the States were not to be superseded by the Federal
Act unless that was the clear and manifest purpose of Congress. Such a purpose may be evidenced in several ways. The scheme of federal regulation may
be so pervasive as to make reasonable the inference that Congress left no room
for the States to supplement it. Or the Act of Congress may touch a field in
which the federal interest is so dominant that the federal system will be assumed to preclude enforcement of state laws on the same subject. Likewise,
the object sought to be obtained by the federal law and the character of obligations imposed by it may reveal the same purpose. Or the state policy may produce a result inconsistent with the objective of the federal statute. It is often a
perplexing question whether Congress has precluded state action or by the
choice of selective regulatory measures has left the police power of the States
undisturbed except as the state and federal regulations collide.19

This passage has a Job-like quality, for what the Court giveth in the
first sentence—the need to show a clear and manifest purpose—it taketh
away in the three enumerated exceptions. Hence the tripartite debate. Ernest Young argues that the Rice presumption should be broadly read to preserve the historic role of the states in local regulation.20 This view favors no
implied preemption.
At the opposite extreme, according to the second school of thought, the
arrival of federal regulation is held to transform the regulatory universe.
This view, which I have defended with Michael Greve, insists that concurrent regulation mistakenly ratchets up government control so that the most
intrusive regulator always wins. It therefore adopts the view of field
preemption: let the regulation cover the topic, and the state intervention is
banned.21 The third position, which Sharkey champions, falls in the middle.
It avoids the strong presumption against concurrent regulation and insists
that there be some demonstration of an actual conflict before the state rules
are shown. Let us turn now to the various positions.
II. THE KESSLER-VLADECK POSITION
In their article entitled A Critical Examination of the FDA’s Efforts to
Preempt Failure-to-Warn Claims, Kessler and Vladeck begin their analysis
of drug preemption cases by addressing institutional issues. They claim
that the FDA performs admirably but is constrained by limited resources,
which leads to mistakes of wrongfully letting dangerous drugs onto the
market. Accordingly, they see the private state tort action as an important
19

331 U.S. 218, 230–32 (1947) (citations omitted) (link).
Ernest Young, Federal Preemption and State Autonomy, in FEDERAL PREEMPTION: STATES‘
POWERS, NATIONAL INTERESTS 249 (Richard A. Epstein & Michael S. Greve eds., 2007).
21
See Richard A. Epstein & Michael S. Greve, Introduction: Preemption in Context, in FEDERAL
PREEMPTION: STATES‘ POWERS, NATIONAL INTERESTS 1 (Richard A. Epstein & Michael S. Greve eds.,
2007); Richard A. Epstein & Michael S. Greve, Conclusion: Preemption Doctrine and Its Limits, in
FEDERAL PREEMPTION: STATES‘ POWERS, NATIONAL INTERESTS 309 (Richard A. Epstein & Michael S.
Greve eds., 2007).
20
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backstop to administrative failure by creating a second chance to correct the
mistakes in the original FDA process.22 They further argue that this ex post
review has significant advantages because it can rely on information about
drug safety, side effects, and effectiveness that accumulates only after a
drug is extensively used on the market. As a textual matter, Kessler and
Vladeck note that the Food and Drug Administration Amendments Act of
2007 (FDAAA)23 offers no safe harbor for pharmaceutical companies because it reaffirms their ability under the FDA‘s warning system to update
their warnings based on newly acquired information.24 Finally, they poohpooh the FDA‘s recent Preemption Preamble which announces its newfound conclusion that its warning labels preempt any state law judgment to
the contrary.25
Initially, much of their proposal builds on the presumption against
preemption, which gains strength from the obvious contrast between the
Medical Device Act, which created preemption in Riegel,26 and the want of
any preemption provision dealing with drugs, as in the Levine case. But
even this point is not as clear as they claim. Levine presents a situation
where the FDA gave explicit approval to the exact treatment, notwithstanding the precise side effect mentioned in the original warning.27 What would
count as new information to render that explicit authorization obsolete? The
mere occurrence of the identified side effect can‘t do it because it was
warned of in advance. And in Levine the sketchy record reveals no evidence collected after the drug hit the market indicating a higher incidence of
this failure (and perhaps others) that might call for a reevaluation of the
risk/reward ratio for that procedure. But making that determination is hard
because new information comes in dribs and drabs, ruling out some defining moment at which the new warning is mandated. Extensive litigation
could easily produce a breakdown of uniformity, which the FDA has rightly
22

Kessler & Vladeck, supra note 13, at 467, 477, 483–95.
Pub. L. 110-85, 120 Stat. 823 (codified as amended in scattered sections of 21 U.S.C.) (link).
24
See Kessler & Vladeck, supra note 13, at 468–69.
25
Id. at 473–74. For a critical discussion of the FDA maneuver, see Catherine M. Sharkey,
Preemption by Preamble: Federal Agencies and the Federalization of Tort Law, 56 DEPAUL L. REV.
227 (2007).
26
See David Vladeck, Summary of Remarks to Medical Device Preemption Conference Participants (July 22, 2008) (discussing Professor Vladeck‘s rejection of Riegel) (upublished manuscript, on
file with author).
27
On this point, the evidence seems powerful:
The bottom line is that the Levine Court upheld common-law actions for negligence and failure-towarn in the face of not one, but two, specific determinations by the FDA regarding the precise regulated risk. The FDA-approved label warned of the risk of harm that transpired in the case . . .
[and,] [a]fter initial approval, the manufacturer proposed a different warning to the FDA . . . and
was told to ―[r]etain verbiage in current label.‖
Catherine M. Sharkey, Products Liability Preemption: An Institutional Approach, 76 GEO. WASH. L.
REV. 449, 507 (2008), available at http://docs.law.gwu.edu/stdg/gwlr/issues/pdf/Sharkey_76-3.pdf
(link).
23
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decried. The FDAAA does not solve that issue.
In addition, the structural flaws in the Kessler-Vladeck approach are
still more profound because of the simplistic way that they integrate the litigation process with the FDA approval process. Kessler and Vladeck consider only one kind of error in the drug approval process: its willingness to
allow dangerous drugs, like Vioxx, on the market. But two kinds of errors
are evident: letting drugs on the market that should be kept off and taking
drugs off of the market that should be left on. The FDA is buffeted with
strong criticisms as many scholars and industry observers deplore its riskaverse attitude.28 I recently helped organize a conference on the FDA role
in oncology cases with the American Enterprise Institute, where oncology
experts reinforced this point by claiming that the FDA did not have the expertise to do state of the art review.29 Kessler and Vladeck are wrong to
suppose that the undermanned and intellectually outgunned FDA will simply roll over by allowing new treatments onto the market. Quite often these
insecurities translate into a systematic reluctance to let many drugs on the
market, lest the agency has to pay a political price if something goes wrong.
That cautious form of institutional protectionism translates into ever longer
clinical trials and administrative delays. All in all, the real risk is that too
few drugs will reach the market, not too many.
After recognizing these two forms of error in regulation, the role of litigation in the FDA approval process is even more problematic. Where the
FDA incorrectly blocks a drug from entering the market, litigation can do
nothing to correct that error. Where the regulatory process lets drugs correctly on the market, litigation remains costly even if it vindicates the defendant. Worse still, litigation has disastrous consequences if safe and
useful drugs are subject to extensive tort liability. Yet Kessler and Vladeck
consider only the scenario where the permit is incorrectly granted, and litigation rightly imposes liability, presumably at the right financial levels.
Why ignore those possibilities, where judicial intervention through the tort
system may only compound the errors of an overly harsh regulatory regime? In evaluating the role of the tort system, it is wrong to consider only
those instances where it may do some good, albeit at a high cost, while ignoring the frequent instances where its use is either costly or harmful. The
complete analysis must cover all possibilities.
At this point, we must ask whether the error rates in litigation will be
low enough to make their system work. Probably not, for a number of reasons. First, litigation comes too little, too late. The drugs that usually generate the most litigation—such as Rezulin and Vioxx—usually are
28

See, e.g., Anna Wilde Mathews, FDA Taps Chief for Drug Center Amid Scrutiny, WALL ST. J.,
Mar. 11, 2008, at B10; Peter Loftus, Drug Approvals Hit Hurdles, WALL ST. J., Nov. 7, 2007, at B5A.
29
For more information on this conference, entitled Oncology Drug Development: Rethinking FDA
Oversight, including event materials and audio and video recordings, please see the AEI website,
http://www.aei.org/events/eventID.1666,filter.all/event_detail.asp (link).

http://www.law.northwestern.edu/lawreview/colloquy/2008/29/

60

NO RT HW E ST ER N U NI VE RSI T Y LAW RE VIE W C O LLOQ UY

withdrawn before litigation commences. Indeed the plaintiffs‘ bar rightly
free rides on FDA determinations, reducing the social gain from litigation.
Second, Kessler and Vladeck do not defend the soundness of the current tort system whose problems are legion. Litigation does not simply ask
if FDA warnings are adequate. It must also decide knotty questions of causation: did this drug, or the excess amounts of the drug, cause the plaintiff‘s
malady? Would the needed information have changed the plaintiff‘s decision to use the drug? These questions are hard to disentangle for plaintiffs
suffering from multiple ailments treated by multiple drug regimens. Often,
no one knows for sure if a particular drug has been taken at all, taken in the
right amounts, at the right time, or in the prescribed fashion. Likewise, liability determinations cannot isolate the effect of a given warning in any individual case. In contrast, the preemption rule forces the ex ante
determination of the relevant issues, free from the distractions of any complex tort litigation.
The fact patterns of Riegel and Levine illustrate some of the complications in using the litigation process. In Riegel, the treating physician inflated the balloon to ten atmospheres of pressure when it was only rated at
eight atmospheres. He also used the balloon in a patient who was not rated
as a suitable candidate.30 Does his decision to ignore the label restrictions
qualify as medical malpractice? Not if the decision was made by conscious
choice instead of simple neglect. If other treatments have little chance of
success, the doctor may rightly decide to take a long-shot by ignoring the
warnings, and the jury may decline to impose malpractice liability.31 So
forget about preemption for the moment—does it make sense to hold the
manufacturer liable for the physician‘s choice because the outcome may
have been unforeseen, or even foreseen but consciously disregarded? We
are not dealing here with teenagers who speed on tires rated for 80 miles per
hour. We are dealing with devices that go through professional channels
such that the upstream player should never be held accountable for the mistakes of the downstream players. If a state law finds liability, should Medtronic now rate its balloon for use only at six atmospheres—and run the risk
that the people in the seven and eight atmospheres category will go without
treatment? No way.
Similarly, in Levine, we know that the risk of arterial puncture is ever
present. But who has better knowledge of the magnitude of the risk in a
particular patient, the company that supplies Phenergan or the physician
who can look at the condition of the patient‘s veins and arteries? These variations matter because they show that the physician is in the best position to
determine if a treatment that is undesirable in some patients is desirable in
30

Riegel v. Medtronic, Inc., 128 S. Ct. 999, 1005 (2008).
See, e.g., Morlino v. Med. Ctr. of Ocean County, 706 A.2d 721 (N.J. 1998) (holding that disregarding standard instructions on use of Ciprofloxacin is not conclusive evidence of medical malpractice)
(link).
31
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others. It is in fact dangerous for the company to recommend that all physicians avoid the IV push if the other treatment options turn out to be more
dangerous. The field preemption rule thus protects patients from the systematic errors of the tort system. On policy grounds, nothing commends the
Kessler-Vladeck proposal.
III. SHARKEY‘S AGENCY MODEL
Sharkey‘s agency proposal is superior to the Kessler-Vladeck position
because of its greater willingness to accept conflict preemption. Therefore,
her proposal would allow Wyeth to keep its case from the jury if the particular point in dispute was subjected to intensive agency review. In her
words, ―courts need a fine-grained account of the precise regulatory review
conducted by the agency and evidence as to its compatibility with state law
tort claims.‖32 Moreover, that inquiry cannot be made on a blank record,
but is intended ―to facilitate input from federal agencies on these issues.‖33
In doing so, ―it is critical to discern whether the FDA has weighed in on the
precise risk the state tort action likewise seeks to regulate.‖34 In the end, her
position leads to Skidmore deference, which asks whether the agency determination has the ―power to persuade.‖35 This deference in turn depends
on ―the thoroughness evident in its consideration, the validity of its reasoning, [and] its consistency with earlier and later pronouncements.‖36
Sharkey‘s proposal thus allows the FDA to insert itself between a drug
manufacturer and tort liability. But its flexibility comes at too high a price.
The successful application of the Skidmore standard depends in large measure on the number of occasions in which its far-reaching inquiry is needed.
Skidmore involved a one-and-done dispute over whether all workers who
were required to be on-call at night were entitled to overtime pay under the
Fair Labor Standards Act.37 The case needed a single fact determination,
without obvious repetition. The administrative agency only made one key
decision about basic policy, which was done without any knowledge of, or
concern with, the facts and circumstances of any particular case. Skidmore
decided only that the Administrator‘s rulings had to be taken into evidence
in the case, where it was entitled to some respect.38
Those burdens are trivial compared to wading through the normal
complex FDA record. In addition, this onerous task would have to be done
in thousands of separate cases. The sheer weight of litigation would open
32
33
34
35
36
37
38

Sharkey, What Riegel Portends, supra note 1, at 418.
Id.
Id. at 423.
Skidmore v. Swift & Co., 323 U.S. 134, 140 (1944).
Id. See also Sharkey, What Riegel Portends, supra note 1, at 424 n.48.
29 U.S.C. § 207 (2000) (link).
Skidmore, 323 U.S. at 140.

http://www.law.northwestern.edu/lawreview/colloquy/2008/29/

62

NO RT HW E ST ER N U NI VE RSI T Y LAW RE VIE W C O LLOQ UY

up the possibility of third-party depositions of present and past FDA employees, and extensive discovery of FDA doctrines. Skidmore is not scalable, and its huge protracted battles over preemption may only be a prelude
for the underlying litigation. The simplest approach in these cases is to follow the kinds of information that was introduced in Skidmore, namely a
broad statement of policy. In this context, this approach would exclude all
the particular FDA judgments in reviewing the drug, but not the Preemption
Preamble, which would be admissible to give some indication of the FDA‘s
policy. Without this sort of restriction, the Sharkey inquiry in Levine could
collapse into the approach of Kessler and Vladeck, barring preemption
across the board.
The Sharkey proposal would also undermine long-term administrative
stability. As she duly notes, my earlier piece on preemption describes the
dangers of agency flip-flop, often in response to intense lobbying pressures
from all sides.39 For example, if the Preemption Preamble tipped the balance in favor of preemption under Skidmore, that precarious result could be
gone with the next change of the guard in the White House or the FDA.
Given the billions of dollars at stake, that flip-flop will not be a simple random event. It will be a target of opportunity that will embolden lobbyists of
all stripes. Those changes flout any notion of a rule of law as a set of stable
social expectations.40
Finally, Sharkey‘s proposal does not correct the deficient error-cost
analysis in the Kessler-Vladeck plan. Nor does it take into account the
substantive weaknesses of the current duty to warn law in most states, with
the high risks of false positives on liability. The proposal‘s ex ante effects
are also likely to deter new drug innovation by adding private law sanctions
to the impressive administrative obstacles that now impede new drug development. Finally, its helter-skelter results undermine the uniformity that
grounds the public acceptance of the law.
IV. FIELD PREEMPTION
By process of elimination, only field preemption remains standing. I
shall not rehearse the case for this position again here.41 However, I do
wish to add one point that I have since developed elsewhere. It is a mistake
to think that the only ways to secure public health are through some combination of sanctions through the FDA permit system and the tort system.
Right now an impressive role in monitoring product safety is played by in39
Sharkey, What Riegel Portends, supra note 1, at 425 & n.53 (citing Richard A. Epstein, Why the
FDA Must Preempt Tort Litigation: A Critique of Chevron Deference and a Response to Richard Nagareda, 1 J. TORT. L. art. 5, at 15, available at http://www.bepress.com/jtl/vol1/iss1/art5/ (2006) (link)).
40
For my views on this point, see Richard A. Epstein, Why the Modern Administrative State is Inconsistent with the Rule of Law, 3 N.Y.U. J.L. & LIBERTY (forthcoming, 2008).
41
See Richard A. Epstein, Why the FDA Must Preempt Tort Litigation: A Critique of Chevron Deference and a Response to Richard Nagareda, 1 J. TORT. L. art. 5 (2006), available at
http://www.bepress.com/jtl/vol1/iss1/art5/ (link).
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termediate organizations such as the National Comprehensive Cancer Network, which supervises the clinical use of off-label drugs, i.e. those which
are taken for one indication, although they actually received FDA approval
for another.42 This voluntary system is quick on the uptake and gets information on adverse events out to the profession faster than the dilatory FDA
processes and the interminable tort litigation. So, it seems unwise to handle
the issue of drug information by coercion when persuasion is still available.
It is one way in which we can get more for less.

42

See Richard A. Epstein, Against Permititis: Why Voluntary Organizations Should Regulate the
Use of Cancer Drugs, American Enterprise Institute Conference Paper, Mar. 13, 2008,
http://www.aei.org/docLib/20080314_EpsteinPaper.pdf (link).
For the NCCN website, see
http://www.nccn.org/ (link).
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